96 related articles for article (PubMed ID: 15987745)
1. Asymmetric dimethylarginine and kidney disease--marker or mediator?
Vallance P; Leiper J
J Am Soc Nephrol; 2005 Aug; 16(8):2254-6. PubMed ID: 15987745
[No Abstract] [Full Text] [Related]
2. Contrast-induced nephropathy and mortality: possible crucial role of asymmetric dimethylarginine.
Andreotti F; Santucci E; Coluzzi G
J Cardiovasc Med (Hagerstown); 2007 Dec; 8(12):1043. PubMed ID: 18163017
[No Abstract] [Full Text] [Related]
3. Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease?
Zoccali C; Kielstein JT
Curr Opin Nephrol Hypertens; 2006 May; 15(3):314-20. PubMed ID: 16609301
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.
Vallance P; Leiper J
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1023-30. PubMed ID: 15105281
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide deficiency in chronic kidney disease.
Baylis C
Am J Physiol Renal Physiol; 2008 Jan; 294(1):F1-9. PubMed ID: 17928410
[TBL] [Abstract][Full Text] [Related]
6. [Asymmetric dimethylarginine: metabolism, arginine paradox, pathophysiology].
Gilinskiĭ MA
Usp Fiziol Nauk; 2007; 38(3):21-39. PubMed ID: 17977229
[TBL] [Abstract][Full Text] [Related]
7. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study.
Fliser D; Kronenberg F; Kielstein JT; Morath C; Bode-Böger SM; Haller H; Ritz E
J Am Soc Nephrol; 2005 Aug; 16(8):2456-61. PubMed ID: 15930091
[TBL] [Abstract][Full Text] [Related]
8. The endothelium as a target in renal diseases.
Zoccali C
J Nephrol; 2007; 20 Suppl 12():S39-44. PubMed ID: 18050141
[TBL] [Abstract][Full Text] [Related]
9. The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature.
Visser M; Paulus WJ; Vermeulen MA; Richir MC; Davids M; Wisselink W; de Mol BA; van Leeuwen PA
Eur J Heart Fail; 2010 Dec; 12(12):1274-81. PubMed ID: 20923854
[TBL] [Abstract][Full Text] [Related]
10. [Arginine--metabolism and functions in the human organism].
Scibior D; Czeczot H
Postepy Hig Med Dosw (Online); 2004; 58():321-32. PubMed ID: 15459550
[TBL] [Abstract][Full Text] [Related]
11. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism.
Wilcken DE; Sim AS; Wang J; Wang XL
Mol Genet Metab; 2007 Aug; 91(4):309-17; discussion 308. PubMed ID: 17560156
[TBL] [Abstract][Full Text] [Related]
12. Asymmetric dimethylarginine: a molecule responsible for the coexistence of insulin resistance and atherosclerosis via dual nitric oxide synthase inhibition.
Zsuga J; Gesztelyi R; Török J; Kéki S; Bereczki D
Med Hypotheses; 2005; 65(6):1091-8. PubMed ID: 16125868
[TBL] [Abstract][Full Text] [Related]
13. Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice.
Desai A; Zhao Y; Warren JS
Nephrol Dial Transplant; 2008 May; 23(5):1513-20. PubMed ID: 18204093
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine in end-stage renal disease patients: a biomarker modifiable by calcium blockade and angiotensin II antagonism?
Zoccali C
Kidney Int; 2006 Dec; 70(12):2053-5. PubMed ID: 17136131
[TBL] [Abstract][Full Text] [Related]
15. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease.
Bode-Böger SM; Scalera F; Kielstein JT; Martens-Lobenhoffer J; Breithardt G; Fobker M; Reinecke H
J Am Soc Nephrol; 2006 Apr; 17(4):1128-34. PubMed ID: 16481412
[TBL] [Abstract][Full Text] [Related]
16. Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality.
Böger RH; Maas R; Schulze F; Schwedhelm E
Clin Chem Lab Med; 2005; 43(10):1124-9. PubMed ID: 16197309
[TBL] [Abstract][Full Text] [Related]
17. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move.
Zoccali C
J Hypertens; 2006 Apr; 24(4):611-9. PubMed ID: 16531785
[TBL] [Abstract][Full Text] [Related]
18. The clinical significance of asymmetric dimethylarginine.
Siroen MP; Teerlink T; Nijveldt RJ; Prins HA; Richir MC; van Leeuwen PA
Annu Rev Nutr; 2006; 26():203-28. PubMed ID: 16848705
[TBL] [Abstract][Full Text] [Related]
19. [ADMA (asymmetric dimethylarginine)--the inhibitor of nitric oxide (NO) synthesis: a new marker for vascular pathology].
Sela BA
Harefuah; 2005 Sep; 144(9):655-9, 675, 674. PubMed ID: 16218539
[TBL] [Abstract][Full Text] [Related]
20. Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule.
Fliser D
Eur J Clin Invest; 2005 Feb; 35(2):71-9. PubMed ID: 15667575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
